Previous 10 | Next 10 |
BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”) announced today its wholly owned subsidiary, Digital Power Lending, LLC (“ DP Lending ”) has made an additional investme...
Top Penny Stocks News on April 13th After Tuesday posed a bearish turnaround for penny stocks and blue chips at midday, investors are hopeful that Wednesday could be different. In the past few trading days, we’ve seen a sizable amount of volatility for penny stocks . This is ...
Antares Pharma ATRS +49% on ~$1B acquisition deal by Halozyme. Sierra Oncology SRRA +37% GSK to acquire Sierra Oncology for $1.9B to bolster specialty meds. BriaCell Therapeutics (BCTX) +17% receives FDA fast track approval for targeted breast cancer immunotherapy. Hi...
Alzamend Neuro (NASDAQ:ALZN) said it had tied up with contract research organizations Altasciences Clinical Kansas and iResearch Atlanta to manage and conduct its Phase II multiple ascending dose study in patients with mild to moderate Alzheimer’s disease. The Phase IIA study, whi...
Full Data Set from Phase I First-in-Human Helped Establish Doses for Phase IIA Multiple Ascending Dose Study Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products f...
MedAvail Holdings (MDVL) +38%. Aterian (ATER) +23%. Sunshine Biopharma SBFM +17% extends upswing to fourth consecutive day. Biofrontera BFRI +15% on Q4 results. System1 (SST) +13%. SeaChange International SEAC +11% on Q4 results. Lion Group Holding (LGHL) +8%. Zh...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter...
Data confirm the positive topline results announced in December 2021 demonstrating AL001 in plasma is bioequivalent to the marketed lithium carbonate product Results show that the shapes of the lithium plasma concentration versus time curves are similar to marketed pro...
Shares of Alzamend Neuro (ALZN +17.6%) are significantly higher today after a 10%+ owner of shares added to holdings. An SEC filing indicates that Milton Ault III, through Ault Alpha LP, purchased 100K shares at $1.1045 per share for a total value of $110,450. The filing also indicates that A...
Gainers: JX Luxventure (LLL) +214%. Draganfly (DPRO) +83%. Zhangmen Education (ZME) +64%. Antelope Enterprise Holdings Limited (AEHL) +37%. Society Pass (SOPA) +31%. Ever-Glory International Group (EVK) +33%. iQIYI (IQ) +26%. Alzamend Neuro (ALZN) +23%. FreightCar America (RAIL) +24%. Puxin (...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...